A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects
Clinical trial NCT01966224 · COMPLETED
Trial details
- NCT number
- NCT01966224
- Sponsor
- Immunomic Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-09-01
- Primary completion
- 2013-12-01
- Enrollment
- 17
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.